An evolutionary framework for treating pediatric sarcomas
Open Access
- 16 March 2020
- Vol. 126 (11), 2577-2587
- https://doi.org/10.1002/cncr.32777
Abstract
Lessons from extinction can be used in trials designed to pursue a cure for cancer. When cancer cannot be cured, similar strategies may be unwise, and strategies that leverage the adaptations of cancer to therapy should be considered.Keywords
Funding Information
- Pediatric Cancer Foundation
- National Institutes of Health
- National Cancer Institute (K08 CA201638)
This publication has 55 references indexed in Scilit:
- Acidity Generated by the Tumor Microenvironment Drives Local InvasionCancer Research, 2013
- Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomasPediatric Blood & Cancer, 2012
- Children's Oncology Group's 2013 blueprint for research: Bone tumorsPediatric Blood & Cancer, 2012
- Evolutionary dynamics of carcinogenesis and why targeted therapy does not workNature Reviews Cancer, 2012
- Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: A Children's Oncology Group studyPediatric Blood & Cancer, 2009
- Hypoxia and adaptive landscapes in the evolution of carcinogenesisCancer and Metastasis Reviews, 2007
- Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891Leukemia, 2005
- Why do cancers have high aerobic glycolysis?Nature Reviews Cancer, 2004
- Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of BoneNew England Journal of Medicine, 2003
- The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the ExtremityNew England Journal of Medicine, 1986